Top

Published in:

01-08-2017 | Translational Neurosciences - Review Article

Alpha-synuclein and iron: two keys unlocking Parkinson’s disease

Authors: Paul Lingor, Eleonora Carboni, Jan Christoph Koch

Published in: Journal of Neural Transmission | Issue 8/2017

Abstract

Current therapies for Parkinson’s disease (PD) confer symptomatic relief and are particularly efficient in the treatment of motor symptoms in earlier disease stages. However, we are still unable to treat the causes of neurodegeneration by modification of the underlying mechanisms, which is partially due to their insufficient understanding. In this short review, we focus on two pivotal disease mechanisms: alpha-synuclein pathology and dysfunction of iron homeostasis as well as their intricate interaction. Both pathomechanisms have been extensively studied in the past and represent valid targets for disease-modifying pharmacological treatment approaches for PD. We summarize the current attempts to exploit iron chelation and modification of alpha-synuclein pathology as translational therapies in PD and discuss the chances and challenges of prospective disease-modifying approaches.

Acosta-Cabronero J, Cardenas-Blanco A, Betts MJ et al. (2016) The whole-brain pattern of magnetic susceptibility perturbations in Parkinson’s disease. Brain 140(1):118–131. doi:10.1093/brain/aww278 CrossRefPubMed

Affiris (2016) Boost vaccination data encourage continued development of AFFiRiS therapeutic Parkinson’s disease vaccine against alpha-synuclein |Affiris| bringing vaccines to chronic disease. http://www.affiris.com/news/boost-vaccination-data-encourage-continued-development-of-affiris-therapeutic-parkinsons-disease-vaccine-against-alpha-synuclein/. Accessed 23 Dec 2016

Anderson JP, Walker DE, Goldstein JM et al (2006) Phosphorylation of Ser-129 Is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281:29739–29752. doi:10.1074/jbc.M600933200 CrossRefPubMed

Anderson CP, Shen M, Eisenstein RS, Leibold EA (2012) Mammalian iron metabolism and its control by iron regulatory proteins. BBA Mol Cell Res 1823:1468–1483. doi:10.1016/j.bbamcr.2012.05.010

Angot EE, Steiner JA, Hansen C et al (2010) Are synucleinopathies prion-like disorders? Lancet Neurol 9:1128–1138. doi:10.1016/S1474-4422(10)70213-1 CrossRefPubMed

Beekes M, Thomzig A, Schulz-Schaeffer WJ, Burger R (2014) Is there a risk of prion-like disease transmission by Alzheimer- or Parkinson-associated protein particles? Acta Neuropathol 128:463–476. doi:10.1007/s00401-014-1324-9 CrossRefPubMedPubMedCentral

Bergström A-L, Kallunki P, Fog K (2015) Development of passive immunotherapies for synucleinopathies. Mov Disord 31:203–213. doi:10.1002/mds.26481 CrossRefPubMed

Bhullar KS, Rupasinghe HPV (2013) Polyphenols: multipotent therapeutic agents in neurodegenerative diseases. Oxid Med Cell Longev 2013:1–18. doi:10.1155/2013/891748 CrossRef

Binolfi AES, Rasia RM, Bertoncini CW et al (2006) Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement. J Am Chem Soc 128:9893–9901. doi:10.1021/ja0618649 CrossRefPubMed

Boddaert N, Le Quan Sang KH, Rötig A et al (2007) Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 110:401–408. doi:10.1182/blood-2006-12-065433 CrossRefPubMed

Bohic S, Murphy K, Paulus W et al (2008) Intracellular chemical imaging of the developmental phases of human neuromelanin using synchrotron X-ray microspectroscopy. Anal Chem 80:9557–9566. doi:10.1021/ac801817k CrossRefPubMed

Braak H, Del Tredici K, Rüb U et al (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211CrossRefPubMed

Cabantchik ZI, Munnich A, Youdim MB, Devos D (2013) Regional siderosis: a new challenge for iron chelation therapy. Front Pharmacol 4:167. doi:10.3389/fphar.2013.00167 CrossRefPubMedPubMedCentral

Caruana M, Högen T, Levin J et al (2011) Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds. FEBS Lett 585:1113–1120. doi:10.1016/j.febslet.2011.03.046 CrossRefPubMed

Cummings J, Isaacson S, Mills R et al (2014) Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 383:533–540. doi:10.1016/S0140-6736(13)62106-6 CrossRefPubMed

Davies P, Moualla D, Brown DR (2011) Alpha-synuclein is a cellular ferrireductase. PLoS One 6:e15814. doi:10.1371/journal.pone.0015814 CrossRefPubMedPubMedCentral

De Rosa P, Marini ES, Gelmetti V, Valente EM (2015) Candidate genes for Parkinson disease: lessons from pathogenesis. Clin Chim Acta 449:68–76. doi:10.1016/j.cca.2015.04.042 CrossRefPubMed

Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H (2010) Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson’s disease. Acta Neuropathol 119:703–713. doi:10.1007/s00401-010-0665-2 CrossRefPubMed

Devos D, Moreau C, Devedjian JC et al (2014) Targeting chelatable iron as a therapeutic modality in Parkinson’s disease. Antioxid Redox Signal 21:195–210. doi:10.1089/ars.2013.5593 CrossRefPubMedPubMedCentral

Dexter D, Carayon A, Javoy-Agid F et al (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson’s disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114:1953–1975CrossRefPubMed

Double KL, Gerlach M, Schünemann V et al (2003) Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem Pharmacol 66:489–494. doi:10.1016/S0006-2952(03)00293-4 CrossRefPubMed

Ducić T, Carboni E, Lai B et al (2015) Alpha-synuclein regulates neuronal levels of manganese and calcium. ACS Chem Neurosci 6:1769–1779. doi:10.1021/acschemneuro.5b00093 CrossRefPubMed

Dufty BM, Warner LR, Hou ST et al (2007) Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. Am J Pathol 170:1725–1738. doi:10.2353/ajpath.2007.061232 CrossRefPubMedPubMedCentral

Earle KM (1968) Studies on Parkinson’s disease including X-ray fluorescent spectroscopy of formalin fixed brain tissue. J Neuropathol Exp Neurol 27:1–14CrossRefPubMed

Finkelstein DI, Hare DJ, Billings JL et al. (2016) The metal chelator clioquinol improves cognitive, motor function and micro-anatomy of the alpha-synuclein hA53T transgenic mice. ACS Chem Neurosci 7(1):119–129. doi:10.1021/acschemneuro.5b00253 CrossRefPubMed

Galvin JE (2006) Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson’s disease: a case for the selective vulnerability of the substantia nigra. Acta Neuropathol 112:115–126. doi:10.1007/s00401-006-0096-2 CrossRefPubMed

Gasser T, Hardy J, Mizuno Y (2011) Milestones in PD genetics. Mov Disord 26:1042–1048. doi:10.1002/mds.23637 CrossRefPubMed

Gilman S, Koller M, Black RS et al (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64:1553–1562. doi:10.1212/01.WNL.0000159740.16984.3C CrossRefPubMed

Guo JL, Lee VMY (2014) Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat Med 20:130–138. doi:10.1038/nm.3457 CrossRefPubMedPubMedCentral

Halliday GM, Holton JL, Revesz T, Dickson DW (2011) Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol 122:187–204. doi:10.1007/s00401-011-0852-9 CrossRefPubMed

Hare DJ, Double KL (2016) Iron and dopamine: a toxic couple. Brain 139:1026–1035. doi:10.1093/brain/aww022 CrossRefPubMed

Hauser RA, Heritier S, Rowse GJ et al (2016) Droxidopa and reduced falls in a trial of Parkinson disease patients with neurogenic orthostatic hypotension. Clin Neuropharmacol 39:220–226. doi:10.1097/WNF.0000000000000168 CrossRefPubMedPubMedCentral

Hawkes CH, Del Tredici K, Braak H (2007) Parkinson’s disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 33:599–614. doi:10.1111/j.1365-2990.2007.00874.x CrossRefPubMed

He N, Ling H, Ding B et al (2015) Region-specific disturbed iron distribution in early idiopathic Parkinson’s disease measured by quantitative susceptibility mapping. Hum Brain Mapp 36:4407–4420. doi:10.1002/hbm.22928 CrossRefPubMed

Hebron ML, Lonskaya I, Moussa CE-H (2013) Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson’s disease models. Hum Mol Genet 22:3315–3328. doi:10.1093/hmg/ddt192 CrossRefPubMedPubMedCentral

Holmes BB, DeVos SL, Kfoury N et al (2013) Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci USA 110:E3138–E3147. doi:10.1073/pnas.1301440110 CrossRefPubMedPubMedCentral

Inden M, Kitamura Y, Takeuchi H et al (2007) Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. J Neurochem 101:1491–1504. doi:10.1111/j.1471-4159.2006.04440.x CrossRefPubMed

Irwin DJ, Abrams JY, Schonberger LB et al (2013) Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone. JAMA Neurol 70:462–467. doi:10.1001/jamaneurol.2013.1933 CrossRefPubMedPubMedCentral

Kostka M, Högen T, Danzer KM et al (2008) Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers. J Biol Chem 283:10992–11003. doi:10.1074/jbc.M709634200 CrossRefPubMed

Levin J, Högen T, Hillmer AS et al (2011) Generation of ferric iron links oxidative stress to α-synuclein oligomer formation. J Parkinsons Dis 1:205–216. doi:10.3233/JPD-2011-11040 PubMed

Levin J, Schmidt F, Boehm C et al (2014) The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset. Acta Neuropathol 127:779–780. doi:10.1007/s00401-014-1265-3 CrossRefPubMedPubMedCentral

Levin J, Maaß S, Schuberth M et al (2016) The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. J Neural Transm 123:439–445. doi:10.1007/s00702-016-1507-8 CrossRefPubMed

Lewy FH (1912) Paralysis agitans. I. Pathologische anatomie. Handbuch der neurologie

Lhermitte J, Kraus WM, McAlpine D (1924) Original papers: on the occurrence of abnormal deposits of iron in the brain in Parkinsonism with special reference to its localisation. J Neurol Psychopathol 5:195CrossRefPubMedPubMedCentral

Li W, West N, Colla E et al (2005) Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson’s disease-linked mutations. Proc Natl Acad Sci USA 102:2162–2167. doi:10.1073/pnas.0406976102 CrossRefPubMedPubMedCentral

Li J-Y, Englund E, Holton JL et al (2008) Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat Med 14:501–503. doi:10.1038/nm1746 CrossRefPubMed

Li W, Englund E, Widner H et al (2016) Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. Proc Natl Acad Sci USA 113:6544–6549. doi:10.1073/pnas.1605245113 CrossRefPubMedPubMedCentral

Lu Y, Prudent M, Fauvet B et al (2011) Phosphorylation of α-synuclein at Y125 and S129 alters its metal binding properties: implications for understanding the role of α-synuclein in the pathogenesis of Parkinson’s disease and related disorders. ACS Chem Neurosci 2:667–675. doi:10.1021/cn200074d CrossRefPubMedPubMedCentral

Luk KC, Kehm V, Carroll J et al (2012) Pathological-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338:949–953. doi:10.1126/science.1227157 CrossRefPubMedPubMedCentral

Mandler M, Valera E, Rockenstein E et al (2014) Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials. Acta Neuropathol 127:861–879. doi:10.1007/s00401-014-1256-4 CrossRefPubMedPubMedCentral

Mao X, Schimmer AD (2008) The toxicology of Clioquinol. Toxicol Lett 182:1–6. doi:10.1016/j.toxlet.2008.08.015 CrossRefPubMed

Mao X, Ou MT, Karuppagounder SS et al (2016) Pathological -synuclein transmission initiated by binding lymphocyte-activation gene 3. Science 353(6307):aah3374. doi:10.1126/science.aah3374 CrossRefPubMedPubMedCentral

Martin-Bastida A, Lao-Kaim NP, Loane C et al (2017) Motor associations of iron accumulation in deep grey matter nuclei in Parkinson’s disease: a cross-sectional study of iron-related magnetic resonance imaging susceptibility. Eur J Neurol 24(2):357–365. doi:10.1111/ene.13208 CrossRefPubMed

Masliah E, Rockenstein E, Mante M et al (2011) Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 6(4):e19338-17. doi:10.1371/journal.pone.0019338 CrossRef

Masuda-Suzukake M, Nonaka T, Hosokawa M et al (2014) Pathological alpha-synuclein propagates through neural networks. Acta Neuropathol Commun 2:88. doi:10.1186/s40478-014-0088-8 CrossRefPubMedPubMedCentral

Mills E, Dong X-P, Wang F, Xu H (2010) Mechanisms of brain iron transport: insight into neurodegeneration and CNS disorders. Future Med Chem 2:51–64. doi:10.1021/ac901991x CrossRefPubMedPubMedCentral

Oertel W, Schulz JB (2016) Current and experimental treatments of Parkinson disease: a guide for neuroscientists. J Neurochem 139(Suppl 1):325–337. doi:10.1111/jnc.13750 CrossRefPubMed

Ortega R, Carmona A, Roudeau S et al (2016) α-Synuclein over-expression induces increased iron accumulation and redistribution in iron-exposed neurons. Mol Neurobiol 53(3):1925–1934. doi:10.1007/s12035-015-9146-x CrossRefPubMed

Ostrerova-Golts N, Petrucelli L, Hardy J et al (2000) The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 20:6048–6054PubMed

Pagan F, Hebron M, Valadez EH et al (2016) Nilotinib effects in Parkinson’s disease and dementia with Lewy bodies. J Parkinsons Dis 6:503–517. doi:10.3233/JPD-160867 CrossRefPubMedPubMedCentral

Pan-Montojo F, Schwarz M, Winkler C et al (2012) Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep 2:1–12. doi:10.1038/srep00898 CrossRef

Paumier KL, Luk KC, Manfredsson FP et al (2015) Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration. Neurobiol Dis 82:185–199. doi:10.1016/j.nbd.2015.06.003 CrossRefPubMedPubMedCentral

Peelaerts W, Bousset L, Van der Perren A et al (2015) α-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522:340–344. doi:10.1038/nature14547 CrossRefPubMed

Peng Y, Wang C, Xu HH et al (2010) Binding of alpha-synuclein with Fe(III) and with Fe(II) and biological implications of the resultant complexes. J Inorg Biochem 104:365–370. doi:10.1016/j.jinorgbio.2009.11.005 CrossRefPubMed

Polymeropoulos MHM, Lavedan CC, Leroy EE et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276:2045–2047CrossRefPubMed

Rasia RMR, Bertoncini CWC, Marsh DD et al (2005) Structural characterization of copper(II) binding to alpha-synuclein: insights into the bioinorganic chemistry of Parkinson’s disease. Proc Natl Acad Sci USA 102:4294–4299. doi:10.1073/pnas.0407881102 CrossRefPubMedPubMedCentral

Rodriguez JA, Ivanova MI, Sawaya MR et al (2015) Structure of the toxic core of α-synuclein from invisible crystals. Nature 525:486–490. doi:10.1038/nature15368 CrossRefPubMedPubMedCentral

Ryan P, Hynes MJ (2007) The kinetics and mechanisms of the complex formation and antioxidant behaviour of the polyphenols EGCg and ECG with iron(III). J Inorg Biochem 101:585–593. doi:10.1016/j.jinorgbio.2006.12.001 CrossRefPubMed

Salazar J, Mena N, Hunot S et al (2008) Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson’s disease. Proc Natl Acad Sci USA 105:18578–18583. doi:10.1073/pnas.0804373105 CrossRefPubMedPubMedCentral

Sauerbier A, Qamar MA, Rajah T, Chaudhuri KR (2016) New concepts in the pathogenesis and presentation of Parkinson’s disease. Clin Med 16:365–370. doi:10.7861/clinmedicine.16-4-365 CrossRef

Schneeberger A, Tierney L, Mandler M (2015) Active immunization therapies for Parkinson’s disease and multiple system atrophy. Mov Disord 31:214–224. doi:10.1002/mds.26377 CrossRefPubMed

Sigel A, Sigel H, Sigel RKO (2006) Neurodegenerative diseases and metal ions. Wiley, ChichesterCrossRef

Spillantini MG, Schmidt ML, Lee VM et al (1997) Alpha-synuclein in Lewy bodies. Nature 388:839–840. doi:10.1038/42166 CrossRefPubMed

Svensson E, Horváth-Puhó E, Thomsen RW et al (2015) Vagotomy and subsequent risk of Parkinson’s disease. Ann Neurol 78:522–529. doi:10.1002/ana.24448 CrossRefPubMed

Tatenhorst L, Eckermann K, Dambeck V et al (2016) Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease. Acta Neuropathol Commun 4:39. doi:10.1186/s40478-016-0310-y CrossRefPubMedPubMedCentral

Todorich B, Pasquini JM, Garcia CI et al (2009) Oligodendrocytes and myelination: the role of iron. Glia 57:467–478. doi:10.1002/glia.20784 CrossRefPubMed

Trétiakoff C (1919) Contribution à l“étude de l”anatomie pathologique du locus niger de Soemmering avec quelques déductions relatives à la pathogénie des troubles du tonus musculaire et de la maladie de Parkinson

Tuttle MD, Comellas G, Nieuwkoop AJ et al (2016) Solid-state NMR structure of a pathogenic fibril of full-length human α-synuclein. Nat Struct Mol Biol 23:409–415. doi:10.1038/nsmb.3194 CrossRefPubMedPubMedCentral

Uversky VN, Li J, Fink AL (2001) Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson’s disease and heavy metal exposure. J Biol Chem 276:44284–44296. doi:10.1074/jbc.M105343200 CrossRefPubMed

Wagner J, Ryazanov S, Leonov A et al (2013) Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease. Acta Neuropathol. doi:10.1007/s00401-013-1114-9 PubMedPubMedCentral

Wakabayashi K, Takahashi H, Takeda S et al (1988) Parkinson’s disease: the presence of Lewy bodies in Auerbach‘s and Meissner’s plexuses. Acta Neuropathol 76:217–221CrossRefPubMed

Walsh DM, Selkoe DJ (2016) A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration. Nat Rev Neurosci 17:251–260. doi:10.1038/nrn.2016.13 CrossRefPubMed

Wang J-Y, Zhuang Q-Q, Zhu L-B et al (2016) Meta-analysis of brain iron levels of Parkinson’s disease patients determined by postmortem and MRI measurements. Sci Rep 6:36669. doi:10.1038/srep36669 CrossRefPubMedPubMedCentral

Weinreb O, Mandel S, Youdim MBH, Amit T (2013) Targeting dysregulation of brain iron homeostasis in Parkinson’s disease by iron chelators. Free Radic Biol Med 62:52–64. doi:10.1016/j.freeradbiomed.2013.01.017 CrossRefPubMed

Wyse RK, Brundin P, Sherer TB (2016) Nilotinib—differentiating the Hope from the Hype. J Parkinsons Dis 6:519–522. doi:10.3233/JPD-160904 CrossRefPubMedPubMedCentral

Zecca L, Youdim MBH, Riederer P et al (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5:863–873. doi:10.1038/nrn1537 CrossRefPubMed

Zucca FA, Segura-Aguilar J, Ferrari E et al (2015) Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson’s disease. Prog Neurobiol. doi:10.1016/j.pneurobio.2015.09.012 PubMed

Title: Alpha-synuclein and iron: two keys unlocking Parkinson’s disease
Authors: Paul Lingor
Eleonora Carboni
Jan Christoph Koch
Publication date: 01-08-2017
Publisher: Springer Vienna
Published in: Journal of Neural Transmission / Issue 8/2017
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-017-1695-x

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Alpha-synuclein and iron: two keys unlocking Parkinson’s disease

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2017

The impact of Parkinson disease on patients’ sexuality and relationship

Nonmotor fluctuations: phenotypes, pathophysiology, management, and open issues

“An essay on the shaking palsy” 200 years old

Classification of advanced stages of Parkinson’s disease: translation into stratified treatments

Epidemiology of Parkinson’s disease

Magnetic resonance imaging for the diagnosis of Parkinson’s disease